About ARGX

Argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Argenx is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Argenx ability to execute on this focus is enabled by its suite of differentiated technologies. Argenx SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows it to exploit novel and complex targets, and its three antibody engineering technologies are designed to enable it to expand the therapeutic index of its product candidates.
Primary Exchange: NASDAQ
SIC Biological Products, (No Diagnostic Substances)
NAICS Biological Product (except Diagnostic) Manufacturing

ARGX is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 212.2 M 2.1215E+08 234 234 0.17% 0.00165499 770 K 770108
UBIO Proshares UltraPro Nasdaq Biotechnology 28.4 M 2.839E+07 227 227 0.11% 0.00106109 98 K 98318
ADRD Invesco BLDRS Developed Markets 100 ADR Index Fund 33.4 M 3.34E+07 82 82 0.12% 0.00123 41 K 41209
ADRU Invesco BLDRS Europe Select ADR Index Fund 11.6 M 1.16E+07 69 69 0.15% 0.0015 17 K 17461
IBB iShares Nasdaq Biotechnology Index Fund 7.4 B 7.39335E+09 221 221 0.4% 0.004 29.5 M 2.94803E+07
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 2.1 B 2.1E+09 1,002 1002 0.01% 0.000108684 228 K 228443